University of Cambridge > > Biological Chemistry Research Interest Group > Rational Metallodrug Development: Novel Pharmacophores and Mode of Action Investigations

Rational Metallodrug Development: Novel Pharmacophores and Mode of Action Investigations

Add to your list(s) Download to your calendar using vCal

If you have a question about this talk, please contact Alice Wood.

The mode of action of anticancer metallodrugs is crucially dependent on their interactions with biological molecules. Since the discovery of cisplatin, a wide variety of metal complexes have been designed for the treatment of cancer and other diseases as well as for diagnostic purposes. Bioorganometallic chemistry is a thriving field of research and in particular the development of anticancer drugs based on organometallic moieties has received a lot of attention in recent years.

As many established chemotherapeutics have low selectivity for tumor tissue, they cause adverse effects which limit the dose that can be administered. Therefore, we are aiming for the development of targeted and targeting drugs, using organometallic fragments to interact selectively with a biomolecular target or to be selectively transported to and accumulated in tumor tissue.

A brief overview of my groups recent contributions to the field of anticancer bioorganometallics will be given in this lecture, including recent advances in our understanding of the modes of action to support future drug design. This presentation will focus on novel metal-based pharmacophores and the application of novel bioanalytical methods and their development, and the translation of these methods to identify new metal-based pharmacophores with promising biological properties.

This talk is part of the Biological Chemistry Research Interest Group series.

Tell a friend about this talk:

This talk is included in these lists:

Note that ex-directory lists are not shown.


© 2006-2024, University of Cambridge. Contact Us | Help and Documentation | Privacy and Publicity